Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Retained Earnings (2023 - 2025)

Monte Rosa Therapeutics' Retained Earnings history spans 3 years, with the latest figure at -$477.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 14119.31% year-over-year to -$477.2 million; the TTM value through Dec 2025 reached -$477.2 million, down 14119.31%, while the annual FY2025 figure was -$477.2 million, 14119.31% down from the prior year.
  • Retained Earnings reached -$477.2 million in Q4 2025 per GLUE's latest filing, down from -$431.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$1.5 million in Q3 2023 to a low of -$477.2 million in Q4 2025.
  • Average Retained Earnings over 3 years is -$292.7 million, with a median of -$378.8 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: crashed 30965.29% in 2024, then skyrocketed 99.21% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$365.9 million in 2023, then surged by 99.08% to -$3.4 million in 2024, then tumbled by 14119.31% to -$477.2 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Retained Earnings are -$477.2 million (Q4 2025), -$431.1 million (Q3 2025), and -$3.4 million (Q2 2025).